Here are the DEF 14A proxy statements from MBX Biosciences, Inc. (MBX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow MBX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MBX filings page.
MBX Biosciences, Inc. is asking stockholders to vote at a fully virtual 2026 annual meeting on June 4, 2026, held via live webcast. Stockholders of record as of April 10, 2026, when 47,570,485 common shares were outstanding, may vote online, by phone, mail, or during the meeting.
Stockholders will elect two Class II directors, Patrick J. Heron and Edward T. Mathers, to serve until 2029, and vote on ratifying Ernst & Young LLP as independent registered public accounting firm for 2026. MBX paid Ernst & Young $491,678 in audit fees for 2025 and $944,548 for 2024.
The company has a classified board split into three classes and four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Science and Medicine. As an emerging growth company and smaller reporting company, it uses scaled executive-pay disclosure. In 2025, CEO P. Kent Hawryluk received salary of $625,000, an annual cash bonus of $359,375, and option awards valued at $1,998,092, for total compensation of $2,990,867.